1.
Elysia specializes in creating health economic models that bridge the gap between market access and commercial teams. These models include standard cost-effectiveness, budget impact, burden disease models, and specialized models such as market sizing, forecasting, and portfolio analysis.
Our client, a local affiliate of a global pharmaceutical company, was given a global cost-effectiveness model to localize to their market. In localizing the model two main issues surface: 1) the model structure was not applicable to the local treatment patterns; and 2) the local pricing and market conditions did not fit with the current model’s strategy.
Elysia was engaged to create a new cost-effectiveness model and develop a strategy to frame the value of their product within the local market. After consulting with local key opinion leaders Elysia developed a model structure that fit the local treatment patterns and was simple and transparent enough to be utilized by local decision makers.
The resulting publication can be found here: Estimating the cost-effectiveness of linezolid for the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Taiwan.
2.
Our database analyses work to understand the market, and develop value propositions from both clinical and economic perspectives. We have conducted database analyses from datasets all of the world, and specialize in Taiwan’s National Health Insurance Research Database.
A new medication was being investigated for patients with a failure of two or more prior regimens of different medications. The client was seeking to understand the treatment patterns in Taiwan as well as estimate the number of patients that would qualify for the new medication.
The Elysia team gained access to Taiwan’s National Health Insurance Database, wrote a study protocol, gained IRB approval, and conducted the database analysis. The client was able to understand the treatment patterns, and pathways that would lead to qualification for their drug if it was introduced into the system.
Resulting Publication:
3.
Regional value dossiers are developed for single products over many countries. These are based off the global value dossiers and include localized information through a search of the literature. We also develop value dossiers for submission in Asia to payers to summarize the available evidence and local epidemiology and disease burden.
A global pharmaceutical company had a single product with two related indications and wanted to condense two large US- and EU-centric global value dossiers into a single, concise, regional value dossier.
Elysia utilized the global value dossiers to extract key value propositions and clinical data. A review of the literature was undertaken in Asia to understand local epidemiology, treatment patterns, economics, health outcomes, and reimbursement policy. The final document was tailored to Asia with information for each specific country as available.
4.
In addition to standard database analysis and health economic modeling the Elysia team is well versed in developing strategies to solve both statistical and modeling problems. These projects are designed to solve specific methodological problems or further explore the application of theoretical ideas in the real-world.
Our past work includes publications related to the applicability and methodology of differential pricing, Determining An Optimal Pricing Strategy For International Differential Pricing: A Theoretic Macroeconomic Approach
Predicting and analyzing drug pricing conditions: Do Macroeconomic Conditions Explain Drug Price Variations Across Countries? A Cross-Sectional Analysis, Estimating the price ratios of personalized medicines with biomarker diagnostics across therapeutic areas and markets, and Using Proportional Hazard Models to Predict Price Changes of Oncology Drugs in the United States
Developing models in limited sample sizes and a technique to estimate population means from survey data: Estimating Markov Chain Transition Matrices in Limited Data Samples: A Monte Carlo Experiment, and Using the weighted interval midpoint estimator (wime) to estimate a population mean from interval data.
Developing a framework for the use of big data in HEOR: Precision Heor: Using Big Data to Develop a Personalized Modeling Framework
5.
Literature searches can be internal queries or used for evidence development and publication
We conduct two main types of literature searches for clients: 1) searches with intent to publish the results; and 2) searches to solve a question within the organization.
A client was working in a disease area where the landscape was quickly changing. They were interested in searching the literature to find all of the cost-effectiveness models within the disease area.
Elysia was engaged to conduct the search and review the materials. Key data was extracted from each study and organized in a visually appealing manner so the client could understand the current trend in modeling techniques, results, and assumptions overtime to better position their future studies.
6.
What is it worth to conduct more research on an important healthcare question versus making a decision based on the knowledge we already have? This question can be explored through value of information (VOI) analyses, which among other uses can help set research priorities when research funding is limited and choices must be made.
A pharmaceutical company has gathered promising evidence for two groundbreaking drugs for two different clinical categories, however the evidence is still uncertain because it was collected from a small study sample of patients.
The company wants to conduct additional research to reduce the uncertainty, but currently only has enough funding to conduct one clinical trial. Which clinical trial should they choose?
The Elysia team can utilize the current, uncertain evidence base to estimate how much value is generated by reducing uncertainty in both clinical trials. The trial that has the highest potential value is the trial that should be funded.